News
KSTX 89.1 FM to Air Special Series on San Antonio’s Bioscience Community, Partnership with BioMed SA Expands Series’ Awareness
“BIOSCIENCE BREAKTHROUGHS” TO AIR THROUGHOUT THE DAY, AUG. 30 – SEPT. 10 SAN ...
Global medical technology leader BD bringing North American professional services headquarters to San Antonio
Nearly 300 new jobs add growth to local biosciences industry BD (Becton, Dickinson and Company), a ...
Events
16th Annual Trauma Symposium
16th Annual Trauma SymposiumAug. 30 – Sept. 1, 2010Marriott RivercenterSan Antonio, Texas A ...Looking Beyond the Science: Career Advancement Strategies
HBA San Antonio Chapter - Women in ScienceSeptember 15, 20105:30 - 8:00 pmGreehey Children's Cancer Research ...Industry Publications
The Mission
The Mission is published by the University of Texas Health Science Center.
UTSA Discovery
UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...
GenSpera Inc. has reached a milestone in the development of its investigational cancer drug.
In a phase 1 clinical study, doctors at the University of Wisconsin Carbone Cancer Center in Madison treated the first patient with GenSpera’s cancer chemotherapeutic agent G-202.
The phase 1 clinical study is designed to treat up to 30 patients with cancers that have progressed even after treatment with other anti-cancer therapies. The study will determine the safety, tolerability and effect the drug has on the human body. Researchers will also study how effective the drug is in treating solid tumors.
G-202 is designed to target the blood vessels in solid tumors in order to destroy the tumor’s blood supply.
San Antonio-based GenSpera is a development stage oncology company.
